Cathal Friel, Executive Chairman, Open Orphan
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations. Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD. In addition, Open Orphan is also developing the world's first COVID-19 human challenge study model as part of the Human Challenge Programme and has signed a reservation contract with the UK Government for the first three COVID-19 vaccine challenge studies.
Michael Rowan, CEO and Andrew Diamond CFO, Active Energy Group
Active Energy Group plc is a London listed (AIM: AEG) renewable energy company focused on second generation biomass products that have the potential to transform the traditional coal fired-power industry and existing renewable biomass industry. To complement these activities AEG is developing an existing lumber business and a renewable forestry management business. With a base in Lumberton, North Carolina, AEG is on the brink of completing its innovative CoalSwitch™ plant, that will produce CoalSwitch™, a black pellet, biomass-based fuel that utilises low-value forestry, and agricultural residues and energy crops.
Graham Clarke, CEO, Emmerson
Emmerson plc (LON:EML) is moving to AIM shortly. Its primary focus is on developing the Khemisset low cost high margin potash project located in Northern Morocco. Khemisset has a large JORC Resource Estimate (2012) of 537Mt @ 9.24% K2O and significant exploration potential. Khemisset is perfectly located to capitalise on the expected growth of African fertiliser consumption whilst also located close to European markets. This unique positioning means the Project will receive a premium netback price compared to existing potash producers. The Feasibility Study released in June 2020 indicated Khemisset has the potential to be among the lowest capital cost and one of the highest margin development stage potash projects in the world. The outstanding economics include a post-tax NPV10 of approximately US$1.4 billion using Argus price forecasts.
Tim McCarthy, Chairman & Dr Simon Ward, CEO, Incanthera
Incanthera plc (AQSE: INC) is a UK oncology-focused, targeted drug development company originating from the Institute of Cancer Therapeutics, University of Bradford (UoB). The Company’s approach is to identify cutting edge technologies in oncology and dermatology, acquire intellectual property rights and prepare those technologies for commercialisation with a partner. Incanthera floated on AQSE on 28 February 2020, raising funds to commercialise the lead asset Sol, a proprietary topical formulation designed to treat solar keratosis and prevent the formation of skin cancers. In September 2020 two successful skin cancer studies surpassed expectations by demonstrating permeation on human skin. Commercial discussions are being undertaken with two Global cosmetic companies amongst several potential partners. In March 2021 the Company raised gross proceeds of £1.14m through an oversubscribed placing with existing and new investors.
Donald Leggatt, Host
Donald Leggatt is Head of Investor Relations at London South East and is a highly experienced financial journalist. He's been on the staff at the Daily Telegraph and later the BBC, was London Correspondent for Forbes Africa and has interviewed many 100’s of CEO’s. He was Editor in Chief at Share Radio, a national financial radio station.